BeijingJune 5, 2026 /PRNewswire/ — On the occasion of the 31st National “Eye Care Day,” the “2026 Youth Vision Health Initiative and Contact Lens Consumption Insight Report” and the strategic cooperation launch event between Aibo Medical and JD Health, hosted by Aibo Medical, a leading domestic ophthalmic enterprise, and supported by People’s Health, were successfully held in Beijing. Nearly 100 attendees, including representatives from People’s Daily Online, ophthalmic experts, relevant leaders from Aibo Medical and JD Health, and multiple authoritative media outlets, gathered to focus on the current state of youth vision health, jointly explore industry development pathways, and collaborate on new measures for the standardized and high-quality development of the eye health industry.
Scene from the “2026 Youth Vision Health Initiative and Contact Lens Consumption Insight Report” and the strategic cooperation launch event between Aibo Medical and JD Health
Zhao Juan, General Manager of People’s Health and General Manager of People’s Sports, stated that eye health is a crucial component of national health, impacting the sense of fulfillment in people’s quality of life; safeguarding nationwide eye health requires sustained and persistent effort. People’s Health looks forward to joining hands with all sectors of society and pooling efforts from multiple parties to jointly promote the dissemination of eye health science knowledge, continuously enhance the health literacy of the entire population, and contribute to the construction of a Healthy China.
Dr. Xie Jiangbing, Founder, Chairman, and General Manager of Aibo Medical, stated that innovation is the foundation of enterprise development; as a national enterprise focused on the ophthalmic field, Aibo Medical is grounded in a deep understanding of clinical ophthalmic needs, combined with its precise R&D capabilities in high-end medical materials and core technological expertise in optical design, to comprehensively empower the entire domestic contact lens industry chain, reshaping product quality to medical-grade standards. In the future, Aibo Medical will strictly adhere to production quality standards and continuously solidify the foundation of the domestic eye health industry.
Li Yanping, Vice President of JD Health and General Manager of JD Health’s Consumer Medical Devices Business, stated that JD Health has become the most comprehensive online platform for ophthalmic medications and vision care products in China; looking ahead, JD Health will continue to leverage its platform advantages and professional medical health capabilities, collaborating with high-quality partners like Aibo Medical to deepen synergy, empower services with technology, safeguard vision with responsibility, and ensure every pair of eyes can see a brighter future, jointly writing a new chapter in the high-quality development of China’s eye health industry.
Focusing on Youth Vision Health, Issuing Scientific Eye Care Initiatives
Youth eye health is an important part of national health. At the event, with support from the People’s Health platform, Aibo Medical, in collaboration with JD Health, released the “2026 Youth Vision Health Initiative” (hereinafter referred to as the “Initiative”) targeting the youth demographic. Based on daily eye care and scientific optometry and fitting, the Initiative outlines six action guidelines: Prevent fatigue, protect both eyes; Prevent dry eyes, avoid indiscriminate use of drops; Regular check-ups, prevent issues before they arise; Optometry first, then fitting; Choose contact lenses, prioritize safety; Wear scientifically, care for them properly. The three parties jointly advocate for young people to establish scientific eye care concepts and safeguard vision health.
During the roundtable discussion segment of the event, guests engaged in an in-depth discussion around the theme “Prevention and Protection of Youth Vision Health.” Tao Yong, Chief Physician of the Ophthalmology Department at Beijing Chaoyang Hospital, shared based on clinical experience that the prevalence of electronic devices has led to prolonged overuse of eyes among young people, who often overlook early warning signs like dry and irritated eyes. Blindly purchasing and overusing eye drops can easily damage the ocular surface and induce issues like dry eye syndrome. Implementing prevention over treatment and moving the eye care threshold forward is key; Dr. Wang Zhao, Director, Deputy General Manager, and R&D Director of Aibo Medical, mentioned that in response to the diverse daily eye-use scenarios of today’s youth and their increasing demands for product quality, Aibo Medical’s R&D team continuously collects clinical feedback and actual consumer usage needs, optimizing product formulations and designs, increasing innovation efforts, and steadily enriching product application functions under existing technological conditions; Li Yanping, Vice President of JD Health and General Manager of JD Health’s Consumer Medical Devices Business, based on platform consumption data analysis, pointed out that young people generally have a consumption misconception of “prioritizing relief over prevention” and introduced the platform’s one-stop eye health service layout, creating an integrated service solution covering product selection, fitting, and care. Science communicator Ning Yuan (online alias “Model Teacher Old Yuan’er”) brought a self-made “Eye Character” model to the event, using tangible teaching aids to break down professional eye care knowledge, transforming dry ophthalmic concepts into engaging and easy-to-understand science content.
Upholding the Bottom Line of Standardized Development, Empowering Iterative Upgrades in the Contact Lens Industry
Wearing contact lenses is one of the important ways for contemporary youth to correct refractive errors. With consumption upgrades, China’s contact lens industry has moved away from extensive scale growth and entered a stage of high-quality development centered on quality and compliance. Against this backdrop, Aibo Medical, in collaboration with JD Health, jointly released the “2026 Contact Lens Consumption Insight Report” (hereinafter referred to as the “Report”). Based on extensive consumption data and industry practices, the Report provides insights into consumption characteristics, assesses technological trends, and supports the stable and long-term development of the industry.
The Report shows that with continuous growth in market demand, the contact lens industry, during its rapid development, still faces issues requiring standardization, such as the circulation of products through informal channels, potential eye health risks due to insufficient compliance among some consumers during wear and use, and a lack of rigor in some marketing promotions. The Report emphasizes that contact lenses are Class III medical devices, and consumer awareness urgently needs to return to medical-grade standards. It calls for promoting the standardization and professionalization of the entire chain from R&D, production, fitting, to sales.
As a leading domestic ophthalmic enterprise, Aibo Medical, leveraging its technological accumulation in precision ophthalmic medical devices such as intraocular lenses for treating cataracts, orthokeratology lenses for myopia control, and implantable collamer lenses for correcting high myopia, has achieved independent breakthroughs in silicone hydrogel materials. Relying on five major technology platforms covering material synthesis, optical design, precision processing, and surface modification, Aibo Medical leads the high-quality development of the domestic contact lens industry. Aibo Medical operates two contact lens production bases, Jiangsu Tianyan Medical and Fujian Aibo Weikang, and has built over 120,000 square meters of R&D and production centers compliant with GMP standards, equipped with multiple highly automated production lines and AOI high-speed optical inspection platforms. It owns Lanbo®, a leader in China’s medical-grade contact lenses, and KAMIYA®, a youthful color contact lens brand, dedicated to providing consumers with safer, more comfortable, and diverse product choices.
Meanwhile, JD Health is continuously improving its new retail model for eye health products, encompassing “online consultation + professional guidance + convenient purchase + after-sales tracking,” while enhancing product accessibility and further promoting the standardization of the sales process.
Starting with the release of the Initiative and the Report, Aibo Medical and JD Health formally signed a strategic cooperation agreement at the event. The two parties will focus on consumer areas such as myopia prevention and control, vision care, and sports health, integrating core advantages in supply chain, product innovation, and user services to jointly enhance the accessibility of high-quality medical products and support the high-quality development of the domestic ophthalmic medical device and sports health industries. New products under the Lanbo® and KAMIYA® brands will be prominently launched on the JD Health platform.
Aibo Medical and JD Health formally sign strategic cooperation
Leveraging the important opportunity of National “Eye Care Day,” the “2026 Youth Vision Health Initiative” and the “2026 Contact Lens Consumption Insight Report” were officially released, alongside the signing of the strategic cooperation agreement with JD Health. This series of activities represents Aibo Medical’s pragmatic implementation efforts in deeply cultivating the eye health sector. In the future, Aibo Medical will adhere to its development vision of “Technology Illuminates Vision,” collaborate with partners from all sectors, leverage technological innovation as a key driver, actively fulfill social responsibilities, and continuously promote the quality upgrade of the domestic ophthalmic industry and the steady improvement of nationwide eye health literacy.